TFIGlobal
TFIGlobal
[tfi_websites]
No Result
View All Result
  • Indo-Pacific
  • Americas
  • Canada
  • Indian Subcontinent
  • West Asia
  • Europe
  • Africa
  • The Caribbean
TFIGlobal
  • Indo-Pacific
  • Americas
  • Canada
  • Indian Subcontinent
  • West Asia
  • Europe
  • Africa
  • The Caribbean
No Result
View All Result
TFIGlobal
TFIGlobal
No Result
View All Result
  • Indo-Pacific
  • Americas
  • Canada
  • Indian Subcontinent
  • West Asia
  • Europe
  • Africa
  • The Caribbean

‘What happens in Rio doesn’t stay in Rio,’ Brazil is exposing the Chinese vaccine like a legend

Akshay Narang by Akshay Narang
January 12, 2021
in Americas
brazil china chinese vaccine
Share on FacebookShare on X

Brazil’s President Jair Bolsonaro is ruining his Chinese President Xi Jinping’s ‘vaccine diplomacy’ dreams. The Xi Jinping administration is making every possible attempt to sell the CoronaVac COVID-19 vaccine developed by China’s Sinovac Biotech. But there is one problem- no one wants to buy it, because of lack of reliability. So, China is desperately looking for validation. But Bolsonaro’s Brazil is continuously exposing just how unreliable the Chinese vaccine is. 

Last month, Brazilian researchers had said that the COVID-19 vaccine developed by Sinovac had an efficacy of over 50%. But the full data was withheld at the company’s request. The officials at Sinovac had then asked Brazilian researchers to delay releasing precise vaccine efficiency data for up to 15 days, on the pretext of consolidating data from global trials. 

Also Read

Quad Foreign Ministers Meeting: Atlanta Buys the Quad Time, Not Trust

China and the Houthis: Why Beijing Risks Its Saudi Oil Ties

Stealth Secrets in Beijing’s Grip: China Holds F-35 Parts After Mystery Hong Kong Detour

The Xi Jinping administration was panicking after Brazilian researchers spoke in terms of 50%+ efficacy. Beijing anyway believes in fudging numbers and therefore the request for delaying precise data fuelled speculation and suspicion about the Chinese vaccine. 

Last week, Brazilian researchers did say that CoronaVac was found to be 78% effective against moderate COVID-19 cases and that it entirely prevented severe cases. But as per Reuters, independent specialists remained sceptic and called for more data from the Phase III trial of Sinovac’s vaccine in Brazil. 

But now China is facing a fresh setback. A Brazilian news website UOL has cited two sources, who had seen the CoronaVac test results in Brazil, to claim that the Chinese vaccine has a general efficacy below 60 per cent. 

Meanwhile, Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to test and produce the Chinese vaccine in Brazil, has dismissed the report as “purely speculative.”

Medical experts and regulators had however criticised what they described as an incomplete disclosure of test results last week. 

China would have been happy or at least satisfied with the 78% efficacy announced last week. But then, Dimas Covas, Director of the Butantan biomedical center, has said that the ongoing analysis had yielded a new “general efficacy”, in addition to the “clinical efficacy” announced earlier. 

So, here is the real thing- CoronaVac is not inspiring much faith. The piecemeal disclosure of results from global test studies is creating the suspicion that Chinese vaccine producers are not subject to the same level of public scrutiny as American or European vaccines. 

China was really desperate for some kind of validation from Brazil, but it seems that Bolsonaro administration is not being very generous towards China. Suspicious information about the Chinese vaccine keeps coming out of Brazil and the Bolsonaro administration has itself been looking for vaccine doses from India. Brazil is thus going to rip apart the Chinese vaccine diplomacy, by exposing the Chinese vaccine before the world at large. 

Tags: BrazilChinaShort takes
ShareTweetSend
Akshay Narang

Akshay Narang

Patriot, Political Analyst, International Relations expert

Also Read

Democrats Win Congress: Trump faces a divided Washington as Democratic leaders prepare to challenge the White House agenda at the US Capitol.

Democrats Win Congress: Gridlock, Vetoes and What Comes Next

November 4, 2026
Russian diesel deal

Diesel, Democrats and Dread: Why American Companies Refuse Russian Diesel

November 2, 2026
Canada's defence bank and Britain's separate defence funding scheme highlight differences in allied approaches to financing military rearmament and strengthening defence industries.

Why Britain won’t join Canada’s defence bank – and what it means

October 27, 2026
Lula wins Brazil election as Brazilian nationalism challenges Trump’s pressure and US influence.

Brazil Is No One’s Backyard: How Trump Handed Lula His Fourth Term

October 26, 2026
Alberta referendum: Voters cast ballots amid debates over provincial independence, Canadian national unity, and Alberta’s oil industry.

Alberta Referendum: Why Alberta Wants to Leave Canada

October 20, 2026
rump endorsed Netanyahu as the US and Israeli leaders stand together against the backdrop of American and Israeli flags, with Jerusalem and the US Capitol symbolising Israel’s strategic ties with Washington and uncertainty over future US support.

Why Trump Endorsed Netanyahu – and Why Israel Is Hedging Its Bets

October 20, 2026
Youtube Twitter Facebook
TFIGlobalTFIGlobal
Right Arm. Round the World. FAST.
  • About Us
  • Contact Us
  • TFIPOST – English
  • TFIPOST हिन्दी
  • Careers
  • Brand Partnerships
  • Terms of use
  • Privacy Policy

[tfi_copyright]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Indo-Pacific
  • Americas
  • Canada
  • Indian Subcontinent
  • West Asia
  • Europe
  • Africa
  • The Caribbean
[tfi_websites]

[tfi_copyright]

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. View our Privacy and Cookie Policy.